HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective

Detalles Bibliográficos
Autores principales: Jovanoski, N, Dario, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747502/
http://dx.doi.org/10.1016/j.jval.2022.09.1477
_version_ 1784849614644445184
author Jovanoski, N
Dario, A
author_facet Jovanoski, N
Dario, A
author_sort Jovanoski, N
collection PubMed
description
format Online
Article
Text
id pubmed-9747502
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-97475022022-12-14 HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective Jovanoski, N Dario, A Value Health Article Published by Elsevier Inc. 2022-12 2022-12-14 /pmc/articles/PMC9747502/ http://dx.doi.org/10.1016/j.jval.2022.09.1477 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Jovanoski, N
Dario, A
HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective
title HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective
title_full HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective
title_fullStr HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective
title_full_unstemmed HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective
title_short HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective
title_sort hta17 cost-effectiveness analysis of tocilizumab for the treatment of covid-19 in hospitalised patients on corticosteroids, from the italian nhs perspective
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747502/
http://dx.doi.org/10.1016/j.jval.2022.09.1477
work_keys_str_mv AT jovanoskin hta17costeffectivenessanalysisoftocilizumabforthetreatmentofcovid19inhospitalisedpatientsoncorticosteroidsfromtheitaliannhsperspective
AT darioa hta17costeffectivenessanalysisoftocilizumabforthetreatmentofcovid19inhospitalisedpatientsoncorticosteroidsfromtheitaliannhsperspective

Ejemplares similares